Objective: The objective of this study was to calculate the positive rate and overall concordance rate of high-risk human papillomavirus (hrHPV) test and cytology using self-sampled and physician-sampled cervicovaginal tests and to compare both specimens. Methods: In collaboration with 3 private hospitals in Sapporo city, 300 women visiting these organizations were enrolled in the study by previously signing an informed consent. From these women, both types of samples (self-obtained and physician-sampled) were obtained at the same time. HrHPV test and cytology were performed on both specimens, and the positive rate and overall concordance rate were calculated to compare both specimens. Results: HrHPV-positive women were 13.7% in physician-sampled specimens and 14.7% in self-sampled specimens, with an overall concordance rate of 96.3% (95% confidence interval [CI]: 94–98%). On the other hand, the positive rate of the cases higher than or equal to atypical squamous cells of undetermined significance (ASCUS) on cytology was different between both groups, that is, 12.3% in physician-obtained and 5.3% in self-sampled specimens; the overall concordance rate was 90.7% (95% CI: 87–94%), indicating an apparent decrease in the positive rate of cytology in self-obtained specimens. Conclusion: HrHPV test and cytology were performed on parallel samples obtained by the patients with a self-sampling tool and by the physician. The positive rate of cytology was considerably different between these specimens, while almost equivalent results were obtained for hrHPV test in both specimens. It was concluded that hrHPV test may be safely and accurately performed on self-obtained cervicovaginal samples by the help of a self-sampling device in the Japanese population as a first screening tool, with equivalent results to physician-obtained specimens.

1.
Vital Statistics in Japan, tabulated by Cancer Information Service, National Cancer Center, Japan [cited 2019 Sep 5] (in Japanese). Available from: https://ganjoho.jp/en/professional/statistics/table_download.html
.
2.
Huh
WK
,
Ault
KA
,
Chelmow
D
,
Davey
DD
,
Goulart
RA
,
Garcia
FA
, et al
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance
.
Gynecol Oncol
.
2015 Feb
;
136
(
2
):
178
82
.
3.
Bessell
T
,
Lang
A
,
Creelman
A
,
Hammond
I
.
Renewal of the national cervical screening program: from evidence-based recommendations to policy and practice
.
Asia-pac J Clin Oncol
.
2014
;
10
(
Suppl 9
):
20
.
4.
Rijkaart
D
,
Berkhof
J
,
Rozendaal
L
,
van Kemenade
F
,
Bulkmans
N
,
Heideman
D
, et al
Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial
.
Lancet Oncol
.
2012
;
13
(
1
):
78
88
. .
5.
National Cervical Screening Program
.
Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding
[cited 2019 Sep 5]. Available from: https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening.
6.
Ketelaars
PJW
,
Bosgraaf
RP
,
Siebers
AG
,
Massuger
LFAG
,
van der Linden
JC
,
Wauters
CAP
, et al
High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: results of the VERA study
.
Prev Med
.
2017
;
101
:
96
101
.
7.
Annual Report RIVM, 2016
.
Dutch National Institute for Public Health and the Environment
.
2017
[cited 2019 Sep 5]. Available from: https://magazines.rivm.nl/en/2017/06/annual-report-rivm-2016.
8.
Smith
M
,
Lew
J
,
Simms
K
,
Canfell
K
.
Impact of HPV sample self-collection for underscreened women in the renewed Cervical Screening Program
.
Med J Aust
.
2016
;
204
(
5
):
1941e
7
.
9.
Hamashima
C
,
Aoki
D
,
Miyagi
E
,
Saito
E
,
Nakayama
T
,
Sagawa
M
, et al
The Japanese guideline for cervical cancer screening
.
Jpn J Clin Oncol
.
2010
;
40
(
6
):
485
502
. (
Japanese with English summary
).
10.
Toki
T
,
Mitsushita
J
,
Mori
A
,
Fujii
S
,
Yamagami
O
,
Kiyosawa
N
, et al
Is self-irrigation smear effective for the detection of intraepithelial lesions of the uterine cervix?
J Jpn Soc Clin Cytol
.
1995
;
34
(
1
):
16
.(
Japanese with English summary
).
11.
Snijders
PJ
,
Verhoef
VM
,
Arbyn
M
,
Ogilvie
G
,
Minozzi
S
,
Banzi
R
, et al
High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening
.
Int J Cancer
.
2013 May 15
;
132
(
10
):
2223
36
.
12.
Arbyn
M
,
Castle
PE
.
Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program
.
Cancer Epidemiol Biomarkers Prev
.
May 2015
;
24
(
5
):
769
72
.
13.
Wright
TC
,
Stoler
MH
,
Behrens
CM
,
Sharma
A
,
Zhang
G
,
Wright
TL
.
Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test
.
Gynecol Oncol
.
2015 Feb
;
136
(
2
):
189
97
.
14.
van Baars
R
,
Bosgraaf
RP
,
ter Harmsel
BW
,
Melchers
WJ
,
Quint
WG
,
Bekkers
RL
.
Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women
.
J Clin Microbiol
.
2012 Dec
;
50
(
12
):
3937
43
.
15.
Arbyn
M
,
Verdoodt
F
,
Snijders
PJ
,
Verhoef
VM
,
Suonio
E
,
Dillner
L
, et al
Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis
.
Lancet Oncol
.
2014 Feb
;
15
(
2
):
172
83
.
16.
Possati-Resende
JC
,
Vazquez
FL
,
Pantano
NP
,
Fregnani
JH
,
Mauad
EC
,
Longatto-Filho
A
.
Implementation of a cervical cancer screening strategy using HPV self-sampling for women living in rural areas
.
Acta Cytol
.
2020
;
64
:
7
15
.
17.
Allende
G
,
Surriabre
P
,
Cáceres
L
,
Bellot
D
,
Ovando
N
,
Torrico
A
, et al
Evaluation of the self-sampling for cervical cancer screening in Bolivia
.
BMC Public Health
.
2019 Jan 17
;
19
(
1
):
80
.
18.
Gottschlich
A
,
Rivera-Andrade
A
,
Grajeda
E
,
Alvarez
C
,
Mendoza Montano
C
,
Meza
R
.
Acceptability of human papillomavirus self-sampling for cervical cancer screening in an indigenous community in Guatemala
.
J Glob Oncol
.
2017 Jan 18
;
3
(
5
):
444
54
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.